Drugs / AMG 732
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06401044 | May 2024 → Feb 2027 expected | endocrine exophthalmos | Amgen | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07438405 | May 2026 → Jan 2028 expected | endocrine exophthalmos | Amgen | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 732 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07438405 ↗ |
| Route | Subcutaneous | “after single subcutaneous (SC) doses” NCT06401044 ↗ |